International guidelines on stage III N2 nonsmall cell lung cancer: surgery or radiotherapy?
Stage III N2 nonsmall cell lung cancer (NSCLC) is a complex disease with poor treatment outcomes. For patients in whom the disease is considered technically resectable, the main treatment options include surgery (with neoadjuvant or adjuvant chemotherapy/neoadjuvant chemoradiotherapy (CRT)) or CRT f...
Main Authors: | Paul Martin Putora, Pawel Leskow, Fiona McDonald, Tim Batchelor, Matthiew Evison |
---|---|
Format: | Article |
Language: | English |
Published: |
European Respiratory Society
2020-02-01
|
Series: | ERJ Open Research |
Online Access: | http://openres.ersjournals.com/content/6/1/00159-2019.full |
Similar Items
-
Interdisciplinary multimodality management of stage III nonsmall cell lung cancer
by: Rudolf M. Huber, et al.
Published: (2019-07-01) -
Surgery for nonsmall cell lung cancer
by: Loïc Lang-Lazdunski
Published: (2013-09-01) -
Outcomes of Hypofractional Tomotherapy in Patients with Stage III Nonsmall Cell Lung Cancer Who Are Not Eligible for Surgery or Concurrent Chemoradiation
by: Jing Li, et al.
Published: (2020-01-01) -
Radio(chemo)therapy in locally advanced nonsmall cell lung cancer
by: Markus Glatzer, et al.
Published: (2016-03-01) -
Adverse events reporting in stage III NSCLC trials investigating surgery and radiotherapy
by: Thomas Iseli, et al.
Published: (2020-09-01)